The incredible ULK improves β-thalassemia
Blood · 2023
DOI: 10.1182/blood.2023021369 ↗Kurz gefasst
Editorial in der Zeitschrift Blood, 2023. Verfasst von Christian Babbs. Beteiligte Einrichtung: MRC Weatherall Institute of Molecular Medicine. Hauptthemen laut MEDLINE: beta-Thalassemia, MicroRNAs. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
aggressive graft-versus-host disease, with resistance to immunosuppression and deaths reported, meaning they should be used with caution. 7The toxicity of checkpoint inhibitor use after allogeneic stem cell transplant brings into sharp focus the importance of identifying patients likely to achieve durable responses to pembrolizumab without allogeneic stem cell transplant.It is also reassuring to know that if transplant is deferred, retreating patients who previously achieved CR is feasible and is a viable bridging strategy to transplant.Checkpoint inhibitors have substantially improved the outcomes of patients with HL, but the optimal treatment setting, sequencing, and combinations require further investigation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- MRC Weatherall Institute of Molecular Medicine.
ORCID-Profile: Christian Babbs
Zitieren
APA
Babbs, C. (2023). The incredible ULK improves β-thalassemia. Blood. https://doi.org/10.1182/blood.2023021369
Vancouver
Babbs C. The incredible ULK improves β-thalassemia. Blood. 2023. doi:10.1182/blood.2023021369
BibTeX
@article{Babbs2023,
author = {Babbs, Christian},
title = {The incredible ULK improves β-thalassemia},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2023021369}
}
EUVIMED